.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

The OncLive Insider app is live!
CME Opportunities

SpecialtySee All >

Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

Corey J. Langer, MD

EP. 1: Looking Ahead to the Next Game-Changer in Lung Cancer

October 1st 2015

EP. 2: CAR T-Cell Therapy in Lung Cancer

October 1st 2015

EP. 3: Immunotherapy: Potential for Higher Cure Rates in Lung Cancer

October 1st 2015

EP. 4: Applying Immunotherapy Learnings in Melanoma to Lung Cancer

October 1st 2015

EP. 5: Checkpoint Inhibition Squamous Cell and Nonsquamous Cell NSCLC

October 1st 2015

EP. 6: Activity of Afatinib in Lung Cancer

October 1st 2015

EP. 7: LUX-Lung 8: Afatinib Survival Benefit in Squamous NSCLC

October 1st 2015

EP. 8: Benefits of Liquid Biopsies in Lung Cancer

October 1st 2015

EP. 9: EGFR-Resistant Disease in Lung Cancer

October 1st 2015

EP. 10: Role of Gefitinib in EGRF-Mutant NSCLC

October 1st 2015

EP. 11: Changing Treatment Landscape in Advanced Lung Cancer

October 1st 2015